Support Psychiatric Nurses
The GeneSight Psychotropic Test from Myriad Genetics is the category-leading pharmacogenomic test for 62 medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. The GeneSight Test can help inform clinicians about how a patient’s genes may impact how they metabolize and/or respond to certain psychiatric medications. It is designed to provide information that may help reduce the trial-and-error process that often takes place when patients are prescribed certain mental health medications.
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Psychiatric nurses are a critical component in the treatment of depression, anxiety, ADHD and other disorders, with tens of thousands of clinicians ordering the GeneSight Test to help personalize treatment with mental health medications. The Myriad Mental Health Medical Affairs team is committed to supporting psychiatric nurses and their use of personalized medicine tools like the GeneSight Test by advancing the science and education of pharmacogenomics.
The Myriad Mental Health Medical Affairs team is committed to educating psychiatric nurses on the use of personalized medicine tools like the GeneSight Test. To meet this mission, educational resources about test report interpretation, evidence for the clinical and economic utility, cost, and recent publications surrounding psychiatric pharmacogenomic testing are provided.
GeneSight - HCP Psychotropic sample report
GeneSight - HCP MTHFR sample report
GeneSight - HCP Clinician report interpretation...
GeneSight - HCP Report interpretation GYR PGx tool
GeneSight - HCP Report interpretation clinical...
GeneSight - HCP MTHFR report interpretation video
GeneSight - HCP Impact of Dose Reduction Patient Case...
GeneSight - HCP Suboptimal SSRI Response Patient Case...
GeneSight - HCP Weighted Multi-Gene PGx Case Study...
GeneSight - HCP Elderly Patient ID Card case study
GeneSight - HCP Med Failure Patient ID Card case study
GeneSight - HCP Med Response Patient ID Card case study
GeneSight - HCP Side Effects Patient ID Card case study
GeneSight - HCP PRIME Study information sheet
GeneSight - HCP PRIME Time to Event Analysis Info Sheet
GeneSight - HCP Clinical research summary
GeneSight - HCP Economic clinical study
GeneSight - HCP Medco study information sheet
GeneSight - HCP Financial information sheet
Persistent benefit of pharmacogenomic testing on initial remission and response rates in patients with major depressive disorder
Meta-analysis of Response and Remission Outcomes With a Weighted Multigene Pharmacogenomic Test for Adults with Depression
Real-World Impact of Pharmacogenomic Testion on Medication Use and Healthcare Resource Utilization in Patients With Major Depressive Disorder
Pharmacogenomic (PGx) testing has the potential to be a valuable tool in depression treatment decision-making for primary care providers and community psychiatric providers; however, clinicians may be uncertain of where PGx testing fits into the depression treatment algorithm, how to integrate results into their clinical decision making, and best practices in communicating with patients with major depressive disorder (MDD) regarding PGx testing. This series will educate the learner on what PGx testing can provide the clinician and how the results can be implemented for the benefit of their patients.
Medscape Pharmacogenomics Education Network (PEN)
305-23: Pharmacogenomics: A Primer for Clinicians in Psychiatry
403-25: Advanced Psychopharmacology in Youth: What Works When and Why?
205-24: Precision Healthcare for Mood Disorders
We’re here to help! Please contact our Medical Information Team.
Dr. Rachael Hart Earls
PhD in Molecular Neuroscience
Medical Science Liaison Manager
Dr. Earls helps support pharmacogenomic education efforts, medical strategy, and evidence generation to advance the science of psychiatric pharmacogenomics.
The latest installment of the GeneSight Mental Health Monitor: Special Election Series, shows that as Election Day draws closer, Americans’ anxiety and/or depression around the 2024 Presidential Election remains significantly elevated.
Read moreInfographicsSpecial Election Report
Phase II of GeneSight® Mental Health Monitor Election Survey from Myriad Genetics Shows 41% of Americans Report Feeling Anxious as the Election Draws Closer
Read moreInfographics
Tens of thousands of clinicians have ordered the GeneSight test for 3 million patients and counting. Explore what happens when the GeneSight test becomes part of a clinician’s practice through the testimonials shared below.
Read more
The stories shared on this page are individual healthcare providers’ personal experiences with GeneSight. Others may not have the same experience or outcome. Do not make any changes to your current medications or dosing without consulting your healthcare provider.